Kymriah (tisagenlecleucel, formerly CTL019) is an autologous CAR T-cell therapy, a novel type of immunotherapy in which a patient’s own genetically altered immune cells are used to attack cancer cells. The FDA approved Kymriah in August 2017 for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. In May 2018, the FDA approved a Kymriah supplemental Biologics License Application for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Kymriah is now FDA-approved for 2 distinct indications.
If you have a Hayes login, click here to view the full report on the Knowledge Center.